PeptSense
Create account

Peptide research

Tirzepatide — compounding legality overview

Tirzepatide (Mounjaro, Zepbound) sits in the same regulatory bucket as other GLP-1s: approved drug availability, compounding restrictions, and active FDA enforcement discretion drive federal posture. State boards may publish additional guidance.

Dual GLP-1/GIP compounding rules

Common names: Mounjaro, Zepbound

PeptSense tracks Tirzepatide across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Restricted
Summary
Placeholder curated status for Tirzepatide in US (503a). Replace via admin after human review.
Citation
FDA (placeholder citation — replace in curation)
Effective
Jan. 1, 2024

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.

Create account View pricing

Related research topics

  • tirzepatide compounding pharmacy
  • tirzepatide legality by state
  • 503A tirzepatide

← All peptides · Resources hub